Document is current
Any future updates will be listed below
-
Authors
Lameris, Roeland
Shahine, Adam https://orcid.org/0000-0001-7717-4437
Pellicci, Daniel G. https://orcid.org/0000-0001-5305-2398
Uldrich, Adam P. https://orcid.org/0000-0002-6350-5976
Gras, Stephanie
Le Nours, Jérôme
Groen, Richard W. J.
Vree, Jana https://orcid.org/0000-0001-7871-5952
Reddiex, Scott J. J. https://orcid.org/0000-0002-1047-5718
Quiñones-Parra, Sergio M.
Richardson, Stewart K.
Howell, Amy R.
Zweegman, Sonja
Godfrey, Dale I. https://orcid.org/0000-0002-3009-5472
de Gruijl, Tanja D.
Rossjohn, Jamie https://orcid.org/0000-0002-2020-7522
van der Vliet, Hans J.
- License Information
-
More Information
Article History
Received: 19 December 2019
Accepted: 5 August 2020
First Online: 14 September 2020
Competing interests
: H.J.V. is Chief Scientific Officer of LAVA Therapeutics, a company working on bispecific antibodies. H.J.V. and T.D.G. are shareholders of LAVA Therapeutics. D.I.G. is a member of the scientific advisory board and a shareholder of Avalia Immunotherapies, a company working on NKT cell-based vaccines.
